Key Insights

Highlights

Treatment Research

3 treatments under study, led by Maintenance Treatment Nivolumabipilimumab

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Withdrawn1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05504642Phase 2WithdrawnPrimary

Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer Patients

Showing all 1 trials

Research Network

Common Treatments

  • Maintenance Treatment Nivolumabipilimumab1
  • Concurrent Chemoradioimmunotherapy Nivolumabipilimumab1
  • Prechemoradioimmunotherapy Treatment Nivolumabipilimumab1

Active Sponsors

  • ZKS Köln1
  • Universitätsklinikum Köln1

Top Investigators

Activity Timeline